About DENARASE®
How it works
DENARASE® specifically hydrolyzes the phosphodiester bonds between nucleotides leaving smaller fragments of around 3-5 base pairs. The enzyme is active on all forms of nucleic acids including single-stranded, double-stranded, linear, circular or supercoiled. Best results are obtained when the enzyme is added before the release of DNA.
Production of DENARASE
DENARASE® has been developed for use in commercial manufacturing processes of biologicals and complies with EU GMP regulations. The patented production process uses a gram-positive Bacillus sp. production host, which minimizes the risks of endotoxins in the product. No antibiotics, materials with TSE/BSE risk or raw materials of animal origin are employed in the manufacture of the product.


DENARASE® is available in two quality grades:
DENARASE® for Research and Development (R&D) use &
DENARASE® for manufacturing under GMP.
-
DENARASE® GMP-grade is manufactured under EU GMP conditions
-
DENARASE® R&D-grade is produced in conformity with the ISO 9001 standard, with less strict requirements regarding documentation, storage and distribution
-
From a technical performance perspective, both quality grades are equal and the parameters on the specification are the same. This allows for a seamless transition from early R&D stage towards biopharmaceutical manufacturing under GMP.
-
In order to avoid mix-ups, packaging units of the same size are indicated differently in the product name of the two quality standards: 1000/5000 kU for R&D-grade DENARASE® and 1/5 MU for GMP-grade DENARASE®.
Order & test DENARASE® now!
- R&D-grade
Products for use in research and development
For process development of biologicals such as viral vectors and vaccines. The enzyme cleaves all forms of DNA and RNA and enables a simpler, more efficient downstream process.Purity: ≥ 99%
Activity: > 250 U/µl
Formulation: buffered aqueous glycerol solution
Storage Temperature: -20°C
Estimated Delivery time: 1-2 weeks (depending on region)- Produced in conformity with ISO 9001 standard
- Manufacturing free of animal derived raw materials and antibiotics
- Depending on your application 10 – 60 U/ml is needed
- Net price excluding VAT and shipment costs
Choose your size for DENARASE® R&D-grade:
- GMP-grade
GMP products for biopharmaceutical manufacturing
For GMP manufacturing of biologicals such as viral vectors and vaccines. The enzyme reduces all forms of DNA and RNA and enables a simpler, more efficient downstream process.Purity: ≥ 99%
Activity: > 250 U/µl
Formulation: buffered aqueous glycerol solution
Storage Temperature: -20°C
Estimated Delivery time: 1-2 weeks (depending on region)- Produced under EU GMP conditions
- Manufacturing free of animal derived raw materials and antibiotics
- Dedicated regulatory support for US-market approvals of pharmaceutical products via own US FDA Drug Master File
- Net price excluding VAT and shipment costs
- Free Sample
Products for use in research and development
Activity: > 250 U/µl
Formulation: buffered aqueous glycerol solution
Storage Temperature: -20°C
Estimated Delivery time: 1-2 weeks (depending on region)
- Produced in conformity with ISO 9001 standard
- Manufacturing free of animal derived raw materials and antibiotics
- Depending on your application 10 – 60 U/ml is needed
- Net price excluding VAT and shipment costs

GMP products for biopharmaceutical manufacturing
Activity: > 250 U/µl
Formulation: buffered aqueous glycerol solution
Storage Temperature: -20°C
Estimated Delivery time: 1-2 weeks (depending on region)
- Produced under EU GMP conditions
- Manufacturing free of animal derived raw materials and antibiotics
- Dedicated regulatory support for US-market approvals of pharmaceutical products via own US FDA Drug Master File
- Net price excluding VAT and shipment costs

Not quite ready to buy yet?

Get your free sample DENARASE®!
New customers from the pharmaceutical industry can request a free 25 kU sample for first lab trials.

Powerful kit for analytical support!
DENARASE® ELISA kit: For the quantitative analysis of endonucleases from Serratia marcescens.
Development of DENARASE®
2009-2012
Start of DENARASE® project: Strain selection, development of upstream and purification process
Project started: Application of endonucleases for DNA removal during protein purification
c-LEcta‘s Bacillus strain, an endotoxin-free expression host, yielded highly active DENARASE product. Purity of ≥99 % was achieved after purification.

2012
Manufacturing of DENARASE® under GMP conditions
Requirements of the biopharmaceutical industry for a GMP product were identified
Partnering with a contract manufacturing organization (CMO) to produce DENARASE® under EU GMP conditions
Manufacturing process free of animal derived raw materials and antibiotics was established

2012
Product launch of DENARASE®
DENARASE® fulfills highest quality standards for biopharmaceutical manufacturing
Starting to build a global sales and distribution network for life science customers
Growth of internal quality, production, distribution and sales functions

2017
First DENARASE®-related patents granted
Patents were successfully granted for the production technology of DENARASE® based on recombinant expression in Bacillus

2020
Launch of DENARASE® ELISA Kit
Launch of own ELISA kit for the detection of S. marcescens endonucleases in process-derived samples
Fastest and most sensitive ELISA kit available on the market

2020
COVID-Support
Focused support for customers developing and manufacturing COVID-19 vaccines at unprecedented speed
Concerted efforts of c-LEcta teams with COVID-19 vaccine customers succeeded in the delivery of large, unplanned quantities of DENARASE on short timelines
c-LEcta’s resilient manufacturing and distribution network kept COVID-19 related supply issues to general customers at an absolute minimum

2021
Drug Master File for DENARASE® accepted by FDA
Dedicated regulatory support for US-market approvals of pharmaceutical products via own US FDA Drug Master File.
In addition, certified compliance with the EXCiPACT and ANSI NSF 363 Standard (meeting GMP for pharmaceutical excipients)

2022
Global application of DENARASE® and ELISA Kit in biopharmaceutical manufacturing
DENARASE® and ELISA Kit are established highest-quality products, applied in the manufacturing of viral vectors for Gene therapies and vaccines:
> 150 customers in > 30 countries
DENARASE® is applied in 4 Commercial and 40+ Clinical Phase I-III viral vector manufacturing processes

2023
New sizes of R&D-grade DENARASE® available
c-LEcta has just launched additional sizes of DENARASE® for research and development use.
Being widely applied in biopharmaceutical R&D and manufacturing, DENARASE sizes of 1 MU and 5 MU will now also be available as R&D-grade, in addition to GMP-grade.

Get in touch with our DENARASE® expert team!

Vaishnavi Devarakonda
DENARASE® Sales

Melissa Rangel
DENARASE® Sales
Need support? Contact me!

Cynthia Hofmann-Orsetti
DENARASE® Sales
Need support? Contact me!